Critical Reviews in Oncology Hematology

Papers
(The H4-Index of Critical Reviews in Oncology Hematology is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Harnessing tumor metabolism during cancer treatment: A narrative review of emerging dietary approaches211
Navigating management of localized prostate cancer in the geriatric population155
Skin barrier dysfunction in cutaneous T-cell lymphoma: From pathogenic mechanism of barrier damage to treatment124
A bone paradigm challenging the standard model of myeloma oncogenesis121
Editorial Board116
Instruments and scales for the evaluation of acute radiation dermatitis: A systematic review91
Surface-Enhanced Raman Scattering (SERS) combined with machine learning enables accurate diagnosis of cervical cancer: From molecule to cell to tissue level90
Direct and indirect effects on child neurocognitive development when maternal cancer is diagnosed during pregnancy: What do we know so far?87
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era70
Unveiling the Role of JAK2/STAT3 signaling in chemoresistance of gynecological cancers: From mechanisms to therapeutic implications69
Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system68
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm67
The role of cGAS-STING in remodeling the tumor immune microenvironment induced by radiotherapy65
Current status of locally advanced rectal cancer therapy and future prospects64
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study63
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II58
Letter to the Editor regarding the article “A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs app57
Hurrying up but not rushing, acting and not reacting, good sense and not common sense: Open thoughts and reasonable doubts on COVID-19 vaccination strategies in cancer patients57
Dysregulation of systemic immunity in colorectal cancer and its clinical applications as biomarkers and therapeutics55
Mapping the research landscape of HPV-positive oropharyngeal cancer: a bibliometric analysis55
A non-invasive miRNA-based approach in early diagnosis and therapeutics of oral cancer52
Stereotactic body radiation therapy versus conventional external beam radiation therapy for painful bone metastases: A systematic review and meta-analysis of randomized trials51
Systemic immune-inflammation index as a predictor of survival in non-small cell lung cancer patients undergoing immune checkpoint inhibition: A systematic review and meta-analysis47
Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting44
Advancing tumor vaccines: Overcoming TME challenges, delivery strategies, and biomaterial-based vaccine for enhanced immunotherapy44
Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions43
Efficacy of PD-1/PD-L1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: A systematic review42
Microbiome and lung cancer: carcinogenic mechanisms, early cancer diagnosis, and promising microbial therapies41
The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth41
Development of treatment strategies for advanced HER2-positive gastric cancer: Insights from clinical trials41
Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models40
Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis39
Immunotherapy in OSCC: Current trend and challenges39
Editorial Board37
Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for gastric cancer with peritoneal metastases: A systematic review by the PIPAC UK collaborative37
TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?37
ESO's career development program (2002-2021): Presentation and evaluation37
0.037760019302368